natgillin/translations-raw huggingface dataset:
of 6) until adequate wound healing, then
e rana zadostno ne zapre, nato
of 6) until threat is resolved.
bolnike, mlajše od 6 let), dokler
Of 62 patients with FVIII:C < 1%, 19 developed an inhibitor (31%).
Inhibitor se je razvil pri 19 (31 %) od 62 bolnikov s FVIII:C < 1 %.
Of 646 patients with multiple myeloma who have received at least 1 prior therapy, 318 patients were treated with combination therapy of Caelyx 30 mg/m2 as a one hour intravenous infusion administered on day 4 following bortezomib which is administered at 1.3 mg/m² on days 1, 4, 8, and 11, every three weeks or with bortezomib monotherapy in a phase III clinical trial.
Od 646 bolnikov z diseminiranim plazmocitomom, ki so prejeli najmanj eno vrsto predhodnega zdravljenja, jih je bilo skupaj 318 zdravljenih s kombinirano terapijo z zdravilom Caelyx v odmerku 30 mg/m2 v obliki enourne intravenske infuzije, dane na 4. dan po bortezomibu (le-tega pa so infundirali v odmerku 1,3 mg/m² v 1., 4., 8. in 11. dnevu na vsake tri tedne), oziroma z bortezomibom v monoterapiji v kliničnem preskušanju faze III.
Of 67 patients evaluated for human anti-mouse antibody (HAMA), no responses were noted.
Pri 67 bolnikih, pri katerih so analizirali prisotnost humanih protimišjih protiteles (human anti-mouse antibody – HAMA), teh niso opazili.
Of a total 3,262 subjects in 23 randomised, double-blinded, placebo or standard of care controlled studies, the overall safety profile of epoetin alfa was evaluated in 1,992 anaemic subjects.
Od skupaj 3.262 oseb v 23 randomiziranih, dvojno slepih, s placebom ali standardno nego nadzorovanih študijah, so splošni varnostni profil epoetina alfa ocenili pri 1.992 anemičnih osebah.
of all species, pigment-laden and/or foamy macrophages were also seen in various tissues, consistent with phospholipidosis.
V monocitno-fagocitnem sistemu so pri vseh živalskih vrstah v različnih tkivih opažali s pigmentom napolnjene in/ali penaste makrofage, kar ustreza fosfolipidozi.
of approximately 13 mmol/L, maximal suppression of 24-hour mean RTG was seen with the 300 mg daily dose to approximately 4 mmol/L to 5 mmol/L in patients with type 2 diabetes in phase 1 studies, suggesting a low risk for treatment-induced hypoglycaemia.
V študijah faze I so pri bolnikih s sladkorno boleznijo tipa 2 z začetno vrednostjo praga za izločanje glukoze v ledvicah približno 13 mmol/l pri meritvi 24 ur po 300 mg odmerku opazili največje znižanje tega praga na približno 4 mmol/l do 5 mmol/l, kar kaže, da je tveganje za hipoglikemijo zaradi zdravljenja majhno.
of artemether,
tablet z artemetrom/lumefantrinom
of atazanavir (see section 4.2).
(glejte poglavje 4.2).
of blockade
trajanje blokade
of boosted PREZISTA and the
PREZISTA in kombinacije zdravil
Of CP patients without a baseline CHR, 70% achieved a CHR, median time to CHR was 1 month and median duration of CHR was
Izmed bolnikov v kronični fazi brez popolnega hematološkega odziva ob izhodišču jih je 70 % doseglo popoln hematološki odziv, pri tem je bila mediana časa do tega odziva 1 mesec, mediana trajanja teh odzivov je bila 32,8 meseca.
of CYP2C9 by RTV)
(indukcija in/ali inhibicija CYP2C9 z RTV)
of CYP3A4 (see section 4.5).
poglavje 4.5).
of darunavir (see section 4.2).
drugimi odmerki darunavirja ni
of darunavir (see section 4.2).
drugimi odmerki darunavirja ni (glejte poglavje 4.2).
of erectile dysfunction.
erektilne disfunkcije.
of fosamprenavir (see section 4.2).
drugimi odmerki fosamprenavirja
of indinavir from 800 mg twice daily to 600 mg twice daily may be
intolerance, morda potrebno znižati odmerek indinavirja z
of Invirase used in
zdravila Invirase,
of itraconazole (> 200 mg/day) or
veliki odmerki itrakonazola (> 200 mg/dan)
of Kaletra with tadalafil is not
Kaletra in teh glukokortikoidov ni
of Kaletra with tadalafil is not recommended.
Sočasna uporaba zdravila Kaletra s tadalafilom ni priporočljiva.
Of lixisenatide-treated patients with HbA1c measurement, 79.3% had either a negative antibody status or an antibody concentration below the lower limit of quantification and the other 20.7% of patients had a quantified antibody concentration.
Med bolniki, zdravljenimi z liksisenatidom merjenem z HbA1c , je imelo negativen izvid protiteles ali koncentracijo protiteles pod spodnjo mejo kvantifikacije 79,3 % bolnikov; preostalih 20,7 % je imelo koncentracijo, ki jo je bilo mogoče določiti kvantitativno.
of maraviroc should be decreased to
Odmerke maraviroka je treba zmanjšati na
of match
ujemanja
of midazolam is administered.
drugih CYP3A modulatorjev in
of midazolam is administered.
odmerek midazolama.
Of note, in vitro studies do not fully exclude possible in vivo interactions.
Omeniti pa je treba, da študije in vitro ne izključujejo v celoti možnih interakcij in vivo.
of OATP substrates/inhibitors.
premenilo koncentracije
Of over 1500 patients enrolled in study BM 16549 comparing monthly with daily dosing regimens of ibandronic acid, 14 % and 18 % of patients used histamine (H2) blockers or proton pump inhibitors after one and two years, respectively.
Od več kot 1.500 bolnikov, vključenih v študijo BM 16549, ki je primerjala mesečno jemanje ibandronske kisline z dnevnim, je po enem letu 14 % bolnikov uporabljalo antagoniste histaminskih receptorjev H2 ali zaviralce protonske črpalke, po dveh letih pa 18 % bolnikov.
Of over 1500 patients enrolled in study BM 16549 comparing monthly with daily dosing regimens of ibandronic acid, 14% and 18% of patients used histamine (H2) blockers or proton pump inhibitors after one and two years, respectively.
Od več kot 1.500 bolnikov, vključenih v študijo BM 16549, ki je primerjala mesečno jemanje ibandronske kisline z dnevnim, je po enem letu 14 % bolnikov uporabljalo antagoniste histaminskih receptorjev H2 ali zaviralce protonske črpalke, po dveh letih pa 18 % bolnikov.
of P-gp
zaviranja P-gp
of P-gp by tipranavir/r at steady-
zavira P-gp, v stanju ravnovesja pa
Of patients who had a confirmed response (partial or complete), the median Duration of Response was 23.0 months (95% CI: 20.4, 26.7) in the laBCC cohort and 13.9 months (95% CI: 9.2, NE) in the mBCC cohort.
Od bolnikov s potrjenim odzivom (delnim ali popolnim) je bila mediana trajanja odziva v kohorti z lokalno napredovalim bazalnoceličnim karcinomom 23,0 meseca (95-% interval zaupanja: 20,4 do 26,7), v kohorti z metastatskim bazalnoceličnim karcinomom pa 13,9 meseca (95-% interval zaupanja: 9,2, NE).
Of patients with paired liver biopsies, 63% (10/16) of KANUMA-treated patients had improvement in hepatic steatosis (at least  5% reduction) as measured by morphometry compared to 40% (4/10) of placebo patients.
Pri bolnikih s parnimi jetrnimi biopsijami se je pri 63% (10/16) bolnikov, zdravljenih z zdravilom KANUMA, jetrna steatoza izboljšala (vsaj  5-% zmanjšanje), izmerjeno z morfometrijo, v primerjavi s 40% (4/10) bolnikov s placebom.
of PREZISTA co-administered with
majhnim odmerkom ritonavirja in
of PREZISTA co-administered with
uporaba zdravila PREZISTA z
of pulmonary
UPORABL JENO Z
Of responders in the pivotal study who completed the extension study, 21 out of 22 (96%) sustained their response to Revestive after an additional 2 years of continuous treatment.
Pri 21 bolnikih od 22 (96 %) odzivnih bolnikov v ključni študiji, ki so zaključili podaljšano študijo, je bil ohranjen odziv na zdravilo Revestive po dodatnih dveh letih neprekinjenega zdravljenja.
of rosuvastatin should be
rosuvastatina sme biti
of seizures or risk
že kdaj prej ali so
of subjects during the first several
Farmakokinetika ritonavirja je ostala nespremenjena.
Of the
Izmed
Of the
Od
Of the 1,035 patients treated with sofosbuvir/velpatasvir in the three Phase 3 clinical studies, 1,023 patients were included in the analysis of NS5A RAVs; 7 patients were excluded as they neither achieved sustained virologic response (SVR12) nor had virologic failure and 5 additional patients were excluded as NS5A gene sequencing failed.
Od 1.035 bolnikov, ki so prejemali zdravljenje s sofosbuvirjem/velpatasvirjem v treh kliničnih študijah 3. faze, je bilo 1.023 bolnikov vključenih v analizo RAV NS5A; 7 bolnikov je bilo izključenih, ker niso dosegli niti trajnega virološkega odziva (SVR12) niti virološkega neuspeha, 5 dodatnih bolnikov pa je bilo izključenih zaradi neuspešnega sekvenciranja gena NS5A.
Of the 1,165 patients treated with Picato in the actinic keratosis clinical studies conducted with ingenol mebutate gel, 656 patients (56%) were 65 years and older, while 241 patients (21%) were 75 years and older.
Od 1.165 bolnikov, zdravljenih z zdravilom Picato v kliničnih študijah aktinične keratoze z gelom z ingenol mebutatom, je bilo 656 bolnikov (56 %) starih 65 let ali več, 241 bolnikov (21 %) pa je bilo starih 75 let ali več.
Of the 1,377 reported bleeds observed in 177 of the 213 patients, 1,244 (90.3%) of the bleeds were resolved with 1-2 infusions of NovoEight.
Od opaženih 1.377 krvavitev pri 177 od 213 bolnikov jih je bilo 1.244
Of the 100 patients randomised to Cosentyx 300 mg, 64, 44 and 24 had an ACR 20/50/70 response, respectively.
Med 100 bolniki, ki so bili randomizirani na zdravljenje z zdravilom Cosentyx 300 mg, jih je 64, 44 oziroma 24 doseglo odziv ACR 20, ACR 50 oziroma ACR 70.
Of the 1108 patients who received any treatment in Trial 1 or Trial 2, 1029 (93%) enrolled and received active treatment in Trial 3.
Od 1108 bolnikov, ki so v preskušanju 1 ali preskušanju 2 prejeli kakršno koli zdravljenje, se jih je 1029 (93 %) vključilo v preskušanje 3 in prejelo aktivno zdravljenje.
Of the 12 cases of cystoid macular oedema, 5 were reported as recovered and 7 as ongoing at end of study.
Od 12 primerov cistoidnega makularnega edema so ob koncu študije poročali o 5 ozdravljenih in 7 še trajajočih.
Of the 12 subjects not randomised in the pivotal study, 6 completed 24 months of treatment with Revestive.
Od 12 preiskovancev, ki v ključni študiji niso bili randomizirani, jih je 6 zaključilo 24-mesečno zdravljenje z zdravilom Revestive.
Of the 1226 patients randomised in the study, the median age was 61 years, 58.6% were male, 97.8% had a baseline ECOG performance status (PS) of 0 or 1, and 2.2% had a baseline ECOG performance status (PS) of 2.
Pri 1226 v študiji randomiziranih bolnikih je bila mediana starost 61 let, 58,6 % je bilo moških, 97,8 % jih je imelo izhodiščno stanje zmogljivosti po ECOG 0 ali 1 in 2,2 % jih je imelo izhodiščno stanje zmogljivosti po ECOG 2.
Of the 126 patients, 96 received the recommended dose of ISENTRESS (see section 4.2).
Izmed 126 bolnikov jih je 96 prejemalo priporočeni odmerek zdravila ISENTRESS (glejte poglavje 4.2).
Of the 126 patients, 96 received the recommended dose of ISENTRESS.
Izmed 126 bolnikov jih je 96 prejelo priporočeni odmerek zdravila ISENTRESS.
Of the 126 patients, 96 received the recommended dose of raltegravir.
Od 126 bolnikov jih je 96 prejemalo priporočeni odmerek raltegravirja.
Of the 130 elderly subjects enrolled in the brivaracetam phase 2/3 development program (44 with epilepsy), 100 were 65-74 years of age and 30 were 75-84 years of age.
Od 130 starejših preskušancev, ki so bili vključeni v razvojni program brivaracetama 2./3. faze (44 od teh z epilepsijo), je bilo 100 starih 65–74 let, 30 pa 75–84 let.
Of the 135 (16%) patients with reports of adverse reactions of neutropenia, 13 patients discontinued bosutinib due to neutropenia.
Od 135 (16 %) bolnikov, pri katerih so poročali o neželenem učinku nevtropeniji, jih je 13 prekinilo z jemanjem bosutiniba zaradi nevtropenije.
Of the 138 patients randomised to Cimzia 200 mg every 2 weeks, 92, 68 and 48 had an ACR 20/50/70 response, respectively.
Od 138 bolnikov, ki je randomizirano prejemalo 200 mg zdravila Cimzia vsaka 2 tedna, jih je 92 imelo odziv ACR 20, 68 odziv ACR 50 in 48 odziv ACR 70.
Of the 14 patients whose cyanide exposure was due to something other than smoke inhalation, 10 survived, including seven patients with ‘lethal’ levels of cyanide in the blood.
Izmed 14 bolnikov, pri katerih zastrupitev s cianidom ni bila posledica vdihavanja dima, jih je 10 preživelo, vključno s sedmimi bolniki, ki so imeli v krvi „smrtne“ ravni cianida.
Of the 140 subjects who completed the Study 332 114 subjects (81.4%) had entered the Extension phase.
Od 140 oseb, ki so zaključile študijo 332, je 114 oseb (81,4 %) vstopilo v podaljšano fazo.
Of the 153 zoledronic acid-treated patients and 115 risedronate-treated patients who entered an extended observation study, after a mean duration of follow-up of 3.8 years from time of dosing, the proportion of patients ending the Extended Observation Period due to the need for re-treatment (clinical judgment) was higher for risedronate (48 patients, or 41.7%) compared with zoledronic acid (11 patients, or 7.2%).
Od 153 bolnikov, zdravljenih z zoledronsko kislino, in 115 bolnikov, zdravljenih z risedronatom, ki so bili vključeni v študijo podaljšanega opazovanja, je bil po povprečnem trajanju spremljanja 3,8 let od časa odmerjanja delež bolnikov, ki so zaključili svoje sodelovanje v podaljšanem obdobju opazovanja, ker so potrebovali ponovno zdravljenje (po presoji zdravnika), večji v skupini bolnikov, ki so prejemali risedronat, (48 bolnikov oziroma 41,7 %) kot v skupini bolnikov, ki so prejemali zoledronsko kislino (11 bolnikov oziroma 7,2 %).
Of the 153 zoledronic acid-treated patients and 115 risedronate-treated patients who entered an extended observation study, after a median duration of follow-up of 3.8 years from time of dosing, the proportion of patients ending the Extended Observation Period due to the need for re-treatment (clinical judgment) was higher for risedronate (48 patients, or 41.7%) compared with zoledronic acid (11 patients, or 7.2%).
Od 153 bolnikov, zdravljenih z zoledronsko kislino, in 115 bolnikov, zdravljenih z risedronatom, ki so bili vključeni v študijo podaljšanega opazovanja, je bil po povprečnem trajanju spremljanja 3,8 let od časa odmerjanja delež bolnikov, ki so zaključili svoje sodelovanje v podaljšanem obdobju opazovanja, ker so potrebovali ponovno zdravljenje (po presoji zdravnika), večji v skupini bolnikov, ki so prejemali risedronat, (48 bolnikov oziroma 41,7 %) kot v skupini bolnikov, ki so prejemali zoledronsko kislino (11 bolnikov oziroma 7,2 %).
Of the 16 patients with high titres, 15 received immune tolerance induction (ITI).
15 od 16 bolnikov z visokimi titri je prejelo indukcijo imunske tolerance (ITI).
Of the 16 patients with low titres, ITI was started in 10.
Izmed 16 bolnikov z nizkimi titri so ITI uvedli pri 10.
Of the 163 ALK-positive NSCLC patients who had received prior treatment with an ALK inhibitor, the median age was 52 years (range: 24-80 years); 86.5% of patients were younger than 65 years.
Mediana starost 163 bolnikov z ALK-pozitivnim nedrobnoceličnim pljučnim rakom, ki so bili že prej zdravljeni z zaviralcem ALK, je bila 52 let (od 24 do 80 let); 86,5 % bolnikov je bilo starih manj kot 65 let.
Of the 17 ALL patients, 2 achieved a complete remission (12%; CR) and 2 a partial remission (12%; PR) at varying doses.
Od 17 bolnikov z ALL je pri različnih odmerkih prišlo do popolne remisije pri 2 (12 %; PR), do delne remisije pa pri 2 (12 %; DR).
Of the 17 MCI patients who had a positive PET scan, 6 (35%) were diagnosed with clinical probable AD 36 months later compared to 3 (10%) of 30 who had a negative scan.
Od 17 bolnikov z zmerno kognitivno okvaro, ki so imeli pozitiven rezultat PET-preiskave, jih je 36 mesecev pozneje 6 (35 %) dobilo diagnozo klinično verjetne AB, v primerjavi s 3 (10 %) od 30, ki so imeli negativen rezultat preiskave.
Of the 1826 patients treated with Qutenza in randomized controlled trials, 1089 (59.6%) reported adverse reactions considered related to the medicinal product by the investigator.
Od 1.826 bolnikov, zdravljenih z zdravilom Qutenza v randomiziranih kontroliranih preskušanjih, jih je 1.089 (59,6 %) poročalo o neželenih učnikih, ki so bili po mnenju raziskovalcev povezani z zdravilom.
Of the 187 bleeding episodes in the efficacy analysis, 155 bleeds (83%) were treated with one infusion, 28 bleeds (15%) with two infusions, 3 bleeds (2%) with three infusions and 1 bleed (0.5%) with four infusions.
Izmed 187 epizod krvavitev, vključenih v analizo učinkovitosti, je bilo 155 krvavitev (83 %) zdravljenih z eno infuzijo, 28 krvavitev (15 %) z dvema infuzijama, 3 krvavitve (2 %) s tremi infuzijami in 1 krvavitev (0,5 %) s štirimi infuzijami.
Of the 190 patients with JIA treated with ORENCIA in this study, one (0.5%) patient discontinued due to non-consecutive infusion reactions, consisting of bronchospasm and urticaria.
Od 190 bolnikov z juvenilnim idiopatskim artritisom, ki so se v tej študiji zdravili z zdravilom ORENCIA, je bil en bolnik (0,5%) izključen iz študije zaradi infuzijske reakcije, ki je vključevala bronhospazem in urtikarijo in ni neposredno sledila infundiranju zdravila.
Of the 199 randomized patients, the mean age was 58 years, 64% were male, 68% were Caucasian, and all patients had baseline ECOG Performance Status (PS) of 0 or 1.
Med 199 randomiziranimi bolniki je bila povprečna starost 58 let, 64 % je bilo moških, 68 % je bilo belcev in vsi bolniki so imeli izhodiščni status zmogljivosti (PS) po ECOG 0 ali 1.
Of the 2,403 patients who were included in the placebo-controlled studies, 79% were biologic-naive, 45% were non-biologic failures and 8% were biologic failures (6% were anti-TNF failures, and 2% were anti-p40 failures).
Med 2.403 bolniki, ki so bili vključeni v s placebom kontrolirane študije, jih 79% pred tem še ni prejemalo bioloških zdravil, pri 45% je bilo neuspešno predhodno zdravljenje, ki ni vključevalo bioloških zdravil, pri 8% pa je bilo neuspešno predhodno zdravljenje z biološkimi zdravili (pri 6% z zaviralci TNF in pri 2% z zdravili proti podenoti p40).
Of the 2,510 HCV genotype 1 infected subjects who were treated with regimens containing dasabuvir, ombitasvir and paritaprevir with or without ribavirin (for 8, 12 or 24 weeks) in Phase 2b and 3 clinical trials, a total of 74 subjects (3%) experienced virologic failure (primarily post-treatment relapse).
Virološki neuspeh (primarni recidiv po zdravljenju) se je v kliničnih preskušanjih faze 2b in 3 pojavil pri skupno 74 od 2.510 preiskovancev (3 %), okuženih s HCV genotipa 1 in zdravljenih s shemami, ki so vsebovale dasabuvir, ombitasvir in paritaprevir z ribavirinom ali brez njega (v obdobju 8, 12 ali 24 tednov).
Of the 2,532 randomised intention-to-treat (ITT) patients, a total of 59 patients experienced at least one new vertebral fracture, placebo: 42 (3.37) – Preotact: 17 (1.32), p0.001.
Od 2532 randomiziranih, vključenih bolnic (ITT - " intention-to-treat") je pri približno 59 bolnicah prišlo do najmanj enega novega vretenčnega zloma, in sicer pri 42 (3,37%) v skupini bolnic, ki so prejemale placebo, in pri 17 (1,32%) v skupini bolnic, ki so prejemale zdravilo Preotact; p=0,001.
Of the 2,712 patients treated, 18% were ≥ 65 years of age, while 5% were ≥ 75 years of age.
Od 2.712 zdravljenih bolnikov je bilo 18% bolnikov starih 65 let ali starejših, 5% bolnikov pa starih 75 let ali starejših.
Of the 22 patients stable at week 8, 6 improved at week 12/16 and 4 deteriorated compared with baseline.
Od 22 v 8. tednu stabilnih bolnikov se je pri 6 bolnikih stanje izboljšalo v 12./16. tednu, pri 4 bolnikih pa se je stanje v primerjavi z izhodiščnim stanjem poslabšalo.
Of the 224 (26%) patients with reports of adverse reactions of anaemia, 5 patients discontinued bosutinib due to anaemia.
Od 224 (26 %) bolnikov, pri katerih so poročali o neželenem učinku anemiji, jih je 5 prekinilo z jemanjem bosutiniba zaradi anemije.
Of the 230 patients randomised, 79 patients were assigned to Odomzo 200 mg.
Izmed 230 randomiziranih bolnikov so 79 bolnikom dodelili zdravljenje z zdravilom Odomzo v odmerku 200 mg.
Of the 230 patients, 16 had a diagnosis of Gorlin Syndrome (15 laBCC and 1 mBCC).
Izmed 230 bolnikov jih je 16 imelo diagnozo Gorlinovega sindroma (15 z lokalno napredovalim in 1 z metastatskim bazalnoceličnim karcinomom).
Of the 232 patients enrolled, 224 had at least one post-scan review by the independent committee and were included in the analysis.
Od 232 vključenih bolnikov je bila po slikanju pri 224 opravljena še najmanj ena ocena posnetka s strani neodvisne komisije, in je bila vključena v analizo.
Of the 24 patients treated that had the NNRTI-associated K103N substitution pre-existing at baseline in their HIV-1, 22 maintained virologic suppression after switching to FTC/RPV/TDF.
Izmed 24 zdravljenih bolnikov z že na začetku prisotno z NNRTI povezano substitucijo K103N v HIV-1, jih je po prehodu na FTC/RPV/TDF 22 ohranilo virološko supresijo.
Of the 26 placebo-treated patients, 13 patients subsequently crossed-over to receive siltuximab.
Od 26 bolnikov, ki so sprva prejemali placebo, jih je 13 kasneje prešlo na prejemanje siltuksimaba.
Of the 267 treated patients, the median age was 59 years (range: 40 to 73); 70% of the patients were male; 90% were White, 6% were Black; 42% had a baseline body mass index of at least 30 kg/m2.
Mediana starosti 267 zdravljenih bolnikov je bila 59 let (razpon: 40–73 let); 70 % bolnikov je bilo moških; 90 % je bilo belcev; 6 % je bilo črncev; 42 % je imelo indeks telesne mase najmanj 30 kg/m2.
Of the 271 patients who received romiplostim in ITP clinical trials, 55 (20%) were age 65 and over, and 27 (10%) were 75 and over.
Od 271 bolnikov, ki so romiplostim prejemali v kliničnih preskušanjih ITP, je bilo 55 (20%) starejših od 65 let in 27 (10%) starejših od 75 let.
Of the 278 patients randomised, 277 patients received at least 1 dose of study drug.
Od 278 randomiziranih bolnikov je 277 bolnikov prejelo vsaj 1 odmerek raziskovanega zdravila.
Of the 29 major surgeries, 24 surgeries (82.8%) required a single pre-operative dose to maintain hemostasis during surgery.
Od 29 večjih kirurških posegov je bil pri 24 posegih (82,8 %) potreben en sam odmerek pred operacijo za ohranitev hemostaze med kirurškim posegom.
Of the 29 patients described above that were treated in Study CAC-002-01 3 patients discontinued (all due to AEs), and one patient died.
Od 29 bolnikov, opisanih zgoraj, zdravljenih v študiji CAC-002-01, so trije prekinili študijo (vsi zaradi neželenih učinkov), en bolnik pa je umrl.
Of the 29 patients described above that were treated in Study CAC-002-01 A total of 3patients discontinued (all due to AEs), and one patient died.
Od 29 bolnikov, opisanih zgoraj, zdravljenih v študiji CAC-002-01, so trije prekinili študijo (vsi zaradi neželenih učinkov), en bolnik pa je umrl.
Of the 3 patients with significant pulmonary involvement at screening/baseline (percentage predicted forced vital capacity in the sitting position ranging from 58-67%), two demonstrated clinically meaningful improvements in FVC (+11.5% and +16.0%) in the sitting position by Week 26.
Izmed treh bolnikov s hudo pljučno prizadetostjo ob pregledu/izhodiščni vrednosti (odstotek predvidene forsirane vitalne kapacitete v sedečem položaju od 58 do 67 %) so se pri dveh do 26. tedna pokazale klinično pomembne izboljšave pri FVC (+11,5 % in +16,0 %) v sedečem položaju.
Of the 3,430 plaque psoriasis patients exposed to Cosentyx in clinical studies, a total of 230 patients were 65 years of age or older and 32 patients were 75 years of age or older.
Med 3.430 bolniki s psoriazo s plaki, ki so bili v kliničnih študijah izpostavljeni zdravilu Cosentyx, je bilo skupno 230 bolnikov starih 65 let ali več, 32 bolnikov pa je bilo starih 75 let ali več.
Of the 30 adverse reactions, 2 were reported in 1 out of 31 patients below 6 years of age, none in patients from 6 to 18 years of age and 28 were reported in 18 out of 127 adults.
Od 30 neželenih učinkov sta bila 2 opisana pri 1 od 31 bolnikov, mlajših od 6 let, nobeden pri bolnikih od 6. do 18. leta in 28 pri 18 od 127 odraslih bolnikih.
Of the 32 inhibitor cases of the full patient cohort (n=101), 16 (16%) were classified as high titre (≥ 5 BU/mL) and 16 (16%) as low titre (< 5 BU/mL).
Od 32 primerov inhibitorjev v celotni kohorti bolnikov (n = 101) jih je bilo 16 (16 %) razvrščenih kot z visokim titrom (≥ 5 B.e./ml) in 16 (16 %) kot z nizkim titrom (< 5 B.e./ml).